HCC

According to the developer of TTI-101, the REVERT-Liver Cancer trial is the second of three phase 2 trials involving the agent.

During a Targeted Oncology™ Case-Based Roundtable™ event, Amit Singal, MD, discussed next steps after diagnosing a patient with metastatic hepatocellular carcinoma.

Promise has been shown with serplulimab plus HLX04 for the treatment of advanced hepatocellular carcinoma, according to phase 2 international research.

The phase 2a portion of a study will evaluate fostrox as a triplet in earlier lines of immunotherapy combinations for patients with hepatocellular carcinoma.

Phase 3 results from the combination of rivoceranib and camrelizumab have excited investigators enough to seek FDA approval for patients with unresectable hepatocellular carcinoma.

TPST-1120 shows promising efficacy and safety data in a phase 1b/2 study of the agent among patients with unresectable or metastatic hepatocellular carcinoma.

Promising efficacy has been seen with the use of immunotherapy for the management of patients with hepatocellular carcinoma, Now, durvalumab and tremelimumab combination therapy is being studied for this patient population listed for a liver transplant.

During a Targeted Oncology™ Case-Based Roundtable™ event, Amit Singal, MD, discussed next steps for a patient with a LI-RADS 5 hepatic mass who has cirrhosis, Crohn disease, and a history of variceal bleeding.

In a presentation given during the 2023 National Comprehensive Cancer Network Annual Conference, Mitesh J. Borad, MD, discussed treatment options for advanced hepatocellular carcinoma.

According to early results from CheckMate 040, nivolumab plus cabozantinib with or without ipilimumab showed good clinical activity and survival.

Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed the available therapy options for a patient with advanced hepatocellular carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Richard Finn, MD, discussed how treatment options for patients with hepatocellular carcinoma have advanced in recent years.

JWATM214, an autologous T-cell immunotherapy candidate drug targeting GPC-3 for patients with advanced hepatocellular carcinoma, is now being investigated in a phase 1 trial.

YB-200, an investigational CEACAM antibody, has caught the attend of the FDA.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed what role a biopsy and other procedures might serve in a patient with a LI-RADS 5 liver lesion. This is the first of 2 articles based on this event.

Moving on to the dose-expansion study of a phase 1b/2a trial of fostroxacitabine bralpamide plus lenvatinib in hepatocellular carcinoma, investigators will assess the recommended phase 2 dose of 30 mg.

The upcoming THIO-102 trial will evaluate the safety and efficacy of THIO administered in sequence with pembrolizumab or atezolizumab across multiple tumor types.

Laura A. Dawson, MD, FRCPC, discusses quality-of-life outcomes from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib versus sorafenib alone in hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, Amit Singal, MD, and participants discussed the significance of LEAP-002 and other trials investigating immunotherapy plus tyrosine kinase inhibitor therapy in patients with hepatocellular carcinoma.

In an interview with Targeted Oncology, Laura Dawson, MD, FRCPC, discussed the results of the phase 3 NRG/RTOG 1112 study of SBRT followed by sorafenib compared with sorafenib alone in locally advanced hepatocellular carcinoma.

The first-in-class PPT-1 inhibitor ezurpimtrostat has been granted an orphan drug designation by the FDA for patients with hepatocellular carcinoma.

The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.

Patients with hepatocellular carcinoma treated from 2018 to 2021 experienced better efficacy vs patients treated from 2008 to 2018, according to a real-world study.

Results from the phase 2 Talem trial, presented at the 2023 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with HCC.

Favorable safety and efficacy data were seen with envafolimab, lenvatinib and transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Anti-drug antibodies did not seem to affect how well the STRIDE regimen of durvalumab and tremelimumab or durvalumab alone worked in patients with unresectable hepatocellular carcinoma.

Data from the health-related quality of life analysis of the LEAP-002 study showed similar scores with the addition of pembrolizumab to lenvatinib vs placebo plus lenvatinib in patients with hepatocellular carcinoma.

Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.

Better health-related quality of life outcomes were seen with tislelizumab vs sorafenib in patients with hepatocelluar carcinoma.